AIMI-Triage CXR PTX

K193300

RADLogics, Inc. · cleared 2020-04-08 · product code QFM · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.3)
The AIMI-Triage CXR PTX Application is a notification-only triage workflow tool for use by hospital networks and clinics to identify and help prioritize chest X-rays acquired in the acute setting for review by hospital radiologists. The device operates in parallel to and independent of standard of care image interpretation workflow. Specifically, the device uses an artificial intelligence algorithm to analyze images for features suggestive of moderate to large sized pneumothorax; it makes case-level output available to a PACS/workstation for worklist prioritization or triage.
Algorithmartificial intelligence algorithm, trained via pattern recognition, processes each chest X-ray and flags those that appear to contain a moderate to large sized pneumothorax for urgent radiologist review
source quote (p.4)
The artificial intelligence algorithm, trained via pattern recognition, processes each chest X-ray and flags those that appear to contain a moderate to large sized pneumothorax for urgent radiologist review.
Adaptive (vs locked)FDA source did not state this
PCCPFDA source did not state this
Cybersecurity addressedFDA source did not state this

Validation studies (1)

Retrospective clinical

n=300 images

endpoints: area under the curve (AUC); sensitivity; specificity

Reported performance (3 observations)

sensitivity0.92CI [86%, 96%]
source quote (p.5)
The sensitivity and specificity of the device was 92% (95% CI: [86%, 96%]) and 90% (95% CI: [84%, 95%]), respectively.
specificity0.9CI [84%, 95%]
source quote (p.5)
The sensitivity and specificity of the device was 92% (95% CI: [86%, 96%]) and 90% (95% CI: [84%, 95%]), respectively.
aurocas written: “auc0.967CI [95.0%, 98.4%]
source quote (p.5)
Overall, the device was able to demonstrate an area under the curve (AUC) of 96.7% (95% CI: [95.0%, 98.4%]), which is substantially equivalent to the predicate device, and meets the required performance goal.

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
0
MAUDE reports in code, 12mo
vs code's own 3-yr baseline
0
drift signals on this device

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K193300